Inovio Pharmaceuticals, Inc.

NasdaqCM:INO Stock Report

Market Cap: US$104.7m

Inovio Pharmaceuticals Management

Management criteria checks 3/4

Inovio Pharmaceuticals' CEO is Jacqueline Shea, appointed in May 2022, has a tenure of 2.5 years. total yearly compensation is $2.44M, comprised of 30.8% salary and 69.2% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth $134.93K. The average tenure of the management team and the board of directors is 3.4 years and 5.8 years respectively.

Key information

Jacqueline Shea

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage30.8%
CEO tenure2.5yrs
CEO ownership0.1%
Management average tenure3.4yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

Here's Why We're Watching Inovio Pharmaceuticals' (NASDAQ:INO) Cash Burn Situation

Aug 11
Here's Why We're Watching Inovio Pharmaceuticals' (NASDAQ:INO) Cash Burn Situation

Some Analysts Just Cut Their Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Estimates

May 15
Some Analysts Just Cut Their Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Estimates

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Just Reported And Analysts Have Been Cutting Their Estimates

May 13
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Just Reported And Analysts Have Been Cutting Their Estimates

Is Inovio Pharmaceuticals (NASDAQ:INO) Using Debt Sensibly?

Oct 23
Is Inovio Pharmaceuticals (NASDAQ:INO) Using Debt Sensibly?

Inovio reports positive phase 1/2 results for recurrent respiratory papillomatosis drug

Oct 13

Inovio Pharmaceuticals: Long On Promise, Short On Results

Sep 27

Inovio Pharmaceuticals GAAP EPS of -$0.46 misses by $0.15, revenue of $0.78M beats by $0.26M

Aug 09

Inovio: After All These Years

Jul 19

Inovio: Long-Term Biotech To Own With Several Catalysts Expected In 2022

Apr 15

Inovio Pharmaceuticals (NASDAQ:INO) Has Debt But No Earnings; Should You Worry?

Mar 21
Inovio Pharmaceuticals (NASDAQ:INO) Has Debt But No Earnings; Should You Worry?

Inovio Undervalued On Potential 2022 Catalyst

Jan 26

Calculating The Intrinsic Value Of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Dec 31
Calculating The Intrinsic Value Of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Inovio Pharmaceuticals: Forget The COVID Pump, And Keep Your Eye On The Oncology Side

Nov 18

Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt

Sep 24
Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt

Inovio: Simply Cannot Be Ignored

Sep 03

CEO Compensation Analysis

How has Jacqueline Shea's remuneration changed compared to Inovio Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$113m

Jun 30 2024n/an/a

-US$122m

Mar 31 2024n/an/a

-US$125m

Dec 31 2023US$2mUS$751k

-US$135m

Sep 30 2023n/an/a

-US$165m

Jun 30 2023n/an/a

-US$168m

Mar 31 2023n/an/a

-US$241m

Dec 31 2022US$4mUS$730k

-US$280m

Sep 30 2022n/an/a

-US$332m

Jun 30 2022n/an/a

-US$355m

Mar 31 2022n/an/a

-US$328m

Dec 31 2021US$2mUS$468k

-US$304m

Sep 30 2021n/an/a

-US$221m

Jun 30 2021n/an/a

-US$142m

Mar 31 2021n/an/a

-US$188m

Dec 31 2020US$2mUS$431k

-US$166m

Sep 30 2020n/an/a

-US$180m

Jun 30 2020n/an/a

-US$222m

Mar 31 2020n/an/a

-US$123m

Dec 31 2019US$1mUS$335k

-US$119m

Compensation vs Market: Jacqueline's total compensation ($USD2.44M) is above average for companies of similar size in the US market ($USD647.72K).

Compensation vs Earnings: Jacqueline's compensation has been consistent with company performance over the past year.

CEO

Jacqueline Shea (58 yo)

2.5yrs

Tenure

US$2,438,908

Compensation

Dr. Jacqueline E. Shea, Ph D., serves as Chief Executive Officer & President at Inovio Pharmaceuticals, Inc. since May 10, 2022 and serves as its Director since May 16, 2022. Dr. Shea served as Chief Opera...

Leadership Team

NamePositionTenureCompensationOwnership
Jacqueline Shea
CEO, President & Director2.5yrsUS$2.44m0.13%
$ 134.9k
Peter Kies
Chief Financial Officer22.4yrsUS$1.16m0.095%
$ 99.2k
Laurent Humeau
Chief Scientific Officer & Chairman of the Scientific Advisory Board5.7yrsUS$1.14m0.093%
$ 97.6k
Thomas Hong
Manager of Investor Relationsno datano datano data
Robert Crotty
General Counsel & Chief Compliance Officer3yrsno datano data
E. Brandreth
Senior Vice President of Quality Assuranceno datano datano data
Jeffrey Skolnik
Senior Vice President of Clinical Development4.1yrsno datano data
Robert Juba
Senior Vice President of Biological Manufacturing & Clinical Supply Management4.1yrsno datano data
Shawn Bridy
Senior Vice President of Business Development3.8yrsno datano data
David Liebowitz
Senior Vice President of Early-Stage Clinical Developmentless than a yearno datano data
Michael Sumner
Chief Medical Officer2.4yrsno data0.031%
$ 33.0k
Cheryl Elder
Senior Vice President of Regulatory Affairs1.7yrsno datano data

3.4yrs

Average Tenure

58yo

Average Age

Experienced Management: INO's management team is considered experienced (3.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jacqueline Shea
CEO, President & Director2.5yrsUS$2.44m0.13%
$ 134.9k
Laurent Humeau
Chief Scientific Officer & Chairman of the Scientific Advisory Boardless than a yearUS$1.14m0.093%
$ 97.6k
Wendy Yarno
Independent Director6.9yrsUS$123.69k0.032%
$ 33.5k
Lota Zoth
Independent Director5.8yrsUS$118.69k0.025%
$ 26.3k
Jay Shepard
Independent Director4.8yrsUS$119.31k0.027%
$ 28.2k
Simon Benito
Independent Chairman of Board of Directors20.9yrsUS$151.19k0.038%
$ 40.2k
David B. Weiner
Member of the Scientific Advisory Board & Director8.7yrsUS$201.79k0.32%
$ 330.9k
Stanley Plotkin
Member of Scientific Advisory Board15.4yrsno datano data
Ann Miller
Independent Director5.7yrsUS$126.94k0.030%
$ 30.9k
Roger Dansey
Independent Director3.5yrsUS$108.69k0.026%
$ 27.1k
Rafi Ahmed
Member of Scientific Advisory Board6yrsno datano data

5.8yrs

Average Tenure

67yo

Average Age

Experienced Board: INO's board of directors are considered experienced (5.8 years average tenure).